Clearmind Medicine Inc. (CMND)
| Market Cap | 4.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.25M |
| Shares Out | 1.69M |
| EPS (ttm) | -75.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 719,307 |
| Open | 2.68 |
| Previous Close | 2.60 |
| Day's Range | 2.62 - 3.08 |
| 52-Week Range | 2.52 - 153.00 |
| Beta | 1.69 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 5, 2024 |
About CMND
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly know... [Read more]
News
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been Cured Tel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq,...
Clearmind Medicine Inc (CMND) is the goose that got cooked – trade carefully
Clearmind Medicine Inc. (NASDAQ:CMND) is on the move this week after favourable stock market news. The company dedicates its resources to discovering a cure for cocaine addiction.
Weight loss MEAI: Clearmind Medicine's Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program
Clearmind Medicine (CMND) stock price is flying but risks remain
Clearmind Medicine (NASDAQ: CMND) stock price was among the best-performing in Wall Street on Thursday. The share jumped by more than 32% and reached a high of $5.37.
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space
Clearmind Medicine Announces 1-for-30 Reverse Share Split
Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ...
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
As part of the Company's plan for recompliance, the Company's shareholders approved a reverse stock split on November 14, 2023. Tel Aviv, Israel / Vancouver, Canada, Nov. 17, 2023 (GLOBE NEWSWIRE) -- ...
Clearmind Medicine Announces Shareholders Meeting Results
Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery a...
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery a...
Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th
Tel Aviv, Israel and Vancouver, British Columbia--(Newsfile Corp. - September 28, 2023) - Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY) ("Clearmind" or the "company"), a biotech compan...
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)
NEW YORK, NY / ACCESSWIRE / September 19, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND). About Clearmind Me...
Clearmind Medicine Closes US$2.25 Million Public Offering
Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and de...
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
Tel Aviv, Israel / Vancouver, Canada, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and de...
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery ...
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery a...
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery ...
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and...
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmid...
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CW...
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery an...
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on disco...
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine ...
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
Tel Aviv, Israel / Vancouver, Canada, May 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on disco...